Immediate release fixed dose combination product [Regulatives / Guidelines]

posted by Dr_Dan  – Germany, 2020-03-11 12:47 (1943 d 01:33 ago) – Posting: # 21240
Views: 6,348

Hello ping4santosh,
Even if you aim at substitution indication (improvement of patient's compliance) presenting co-prescription data and therapeutic guidelines recommending the co-administration will not suffice as long as you are unable to present clinical data demonstrating safety and efficacy of the respective combination. IMHO it will be hard to identify a new FDC which can be approved without a phase III study (at least in western Europe).

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,676 registered users;
35 visitors (0 registered, 35 guests [including 14 identified bots]).
Forum time: 15:21 CEST (Europe/Vienna)

Many people tend to look at programming styles and languages like religions:
if you belong to one, you cannot belong to others.
But this analogy is another fallacy.    Niklaus Wirth

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5